A new approach, published in “Cell Reports,” to regenerate inner ear sensory hair cells is said to lay the groundwork for treating chronic noise-induced hearing loss by the company, Frequency Therapeutics, and its co-founders who are drawing on research from Brigham and Women's Hospital (BWH), Harvard Medical School, Mass Eye and Ear Infirmary, and MIT. The program is expected to progress to into human clinical trials within the next 18 months.
The size of the tinnitus population in the United States is nearly 30 million people—or about 10% of the entire population—and the incidence of tinnitus is as high as 26.7% for people ages 65-84 years. Data in this article also confirm that the provision of hearing aids offers substantial benefit to a significant number of people suffering from tinnitus. Evidence also suggests that this information should be more widely disseminated in the audiological and medical communities.